University of Arizona
2 papers in the library · 789 citations · publishing 2006-2026
The Journal of Clinical Psychiatry November 15, 2006 Francisco Moreno, Christopher B. Wiegand, E. Keolani Taitano et al. 786 citations
In a controlled clinical setting, psilocybin was safely administered to individuals with obsessive-compulsive disorder (OCD) and was linked to immediate decreases in core OCD symptoms in several participants.
Journal of Psychopharmacology March 13, 2026 Francisco A. Moreno, Katja Ehrmann Allen, Christopher B. Wiegand et al. 3 citations
Psilocybin, a psychedelic compound, was generally well-tolerated and reduced obsessive-compulsive disorder (OCD) symptoms in a small clinical trial. No serious adverse events, psychotic symptoms, or changes in suicide severity occurred. Psilocybin, but not placebo, significantly lowered scores on the Yale-Brown Obsessive Compulsive Scale. After eight weeks of treatment including at least four high doses, 73.3% of participants responded (at least 35% reduction in symptoms), and 40% achieved remission. Benefits diminished but remained substantial at six months. Higher cumulative doses were linked to greater symptom reduction. Larger trials are needed to confirm efficacy and refine protocols.